✦ LIBER ✦

Comparison of the New Cardioselective Beta-Blocker Nebivolol with Bisoprolol in Hypertension: The Nebivolol, Bisoprolol Multicenter Study (NEBIS)

✍ Scribed by Istvan Czuriga; Igor Riecansky; Juraj Bodnar; Tibor Fulop; Valeria Kruzsicz; Eva Kristof; Istvan Edes

Book ID: 111558210
Publisher: Springer US
Year: 2003
Tongue: English
Weight: 99 KB
Volume: 17
Category: Article
ISSN: 0920-3206
DOI: 10.1023/a:1026180325278

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Integrated cardiac and metabolic effects

Integrated cardiac and metabolic effects of the beta-1-selective blocker nebivolol in physically active patients with essential hypertension.

✍ W. Mainka; W. Schillings; K. Scheele; J. Duperly; H. Ohba; J.V. Fallois; T. Schr 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 126 KB

A Comparison of Two Cardioselective Beta

A Comparison of Two Cardioselective Beta-Blockers with Different Ancillary Properties in the Treatment of Hypertension

✍ Mänttäri, M. ;Eisalo, A. 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 283 KB

Integrated effects of the vasodilating b

Integrated effects of the vasodilating beta-blocker nebivolol on exercise performance, energy metabolism, cardiovascular and neurohormonal parameters in physically active patients with arterial hypertension

✍ Predel, H G; Mainka, W; Schillings, W; Knigge, H; Montiel, J; Fallois, Jv.; Agra 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 129 KB

Evaluation of celiprolol, a new cardiose

Evaluation of celiprolol, a new cardioselective beta1-adrenergic blocker with vasodilating properties, in the treatment of mild to moderate hypertension in the elderly

✍ K. D. Lamon 📂 Article 📅 1991 🏛 Springer US 🌐 English ⚖ 499 KB

Celiprolol hydrochloride is a cardioselective beta 1-adrenergic antagonist with partial agonist activity. The studies discussed were designed to assess celiprolol's pharmacokinetic disposition, its efficacy versus placebo and other beta blockers, its relative safety profile, and its therapeutic rati

A Randomized, Double-Blind, Placebo-Cont

A Randomized, Double-Blind, Placebo-Controlled Parallel-Group Study to Assess the Efficacy and Safety of Nebivolol, a Novel β-Blocker, in Patients With Mild to Moderate Hypertension

✍ Robert J. Weiss; Michael A. Weber; Albert A. Carr; Will A. Sullivan 📂 Article 📅 2007 🏛 Le Jacq Communications, Inc. 🌐 English ⚖ 218 KB